九洲藥業(603456.SH):擬1500萬元參設合夥企業 投資於非上市公司熙華檢測股權
格隆匯3月14日丨九洲藥業(603456.SH)公佈,2023年3月13日,公司全資子公司宏洲投資與寧波君度私募基金管理有限公司(稱“君度管理”)、寧波傑豐弘鳴創業投資合夥企業(有限合夥)(稱“傑豐投資”)、黃喜強、張寧、甘泉和黃勇簽署《寧波君度景明創業投資合夥企業(有限合夥)合夥協議》,共同參與投資寧波君度景明創業投資合夥企業(有限合夥)。合夥企業認繳出資總額為人民幣5510萬元(包含本次投資),宏洲投資將作為有限合夥人以自有資金認繳出資額為人民幣1500萬元,佔合夥企業認繳出資總額的27.22%。
合夥企業專項投資於非上市公司熙華檢測的股權,熙華檢測是一家為全球製藥企業提供高質量、高效率的從成藥性研發到批准上市一體化服務的公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.